ABSTRACT
Binding a monoclonal antibody to tumor associated antigens is an effective method for cancer therapy because these agents can specifically target malignant cells. In fact, monoclonal antibodies are effective agents for diagnosis, grading and treatment of different kinds of cancers. In this research, a new monoclonal antibody against colon cancer cells was prepared and radiolabeling with technetium-99m evaluated. This research was done in three parts: preparation of hybridoma cell against colon cancer cell line [HT29], production of monoclonal antibody, determination of its characterizations and radiolabeling with technetium-99m. mAb-D2 is an IgG1 with affinity constant of 7.2x10[9] M[-1] which can recognize CEA in tumor cells. Radiolabeling showed that [99m]Tc-HYNIC-mAb-D2 complex is stable, immunoradioactive, and has a desirable biodistribution. In this study, we gained a new radiopharmaceutical that may be a good candidate for radioimmunoscintigraphy
Subject(s)
Colonic Neoplasms/diagnostic imaging , Radioimmunodetection , Radiopharmaceuticals , Antibodies, Monoclonal , Technetium Tc 99m MedronateABSTRACT
Binding a monoclonal antibody to tumor associated antigens is an effective method for cancer therapy because these agents can specifically target malignant cells, in fact monoclonal antibodies are effective agents for diagnosis, grading and treatment of different kinds of cancers. In this research, a new monoclonal antibody against colon cancer cells was prepared and antigen concentration in different cells determined by a radioimmunoassay method using iodine [I-125] labeled protein G. 125I-labeled protein G percent binding to white blood cell, HT29, LS180 and MCF7 cell lines were 7.1%, 91.2%, 75.8% and 40.2%, respectively. Regarding importance of monoclonal antibody applications, it is necessary to find an efficient method for their evaluation in cancer therapy. In this method, a radioactive agent with no count restriction was used. Also by this method, amount of the antigen can be easily quantified